Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
Ocugen, a biotechnology firm focused on innovative therapies, announced that its CEO, Dr. Shankar Musunuri, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, from 11 a.m. to 11:30 a.m. EDT. The event will be held at the Nasdaq Market Site in New York City.
Dr. Musunuri will discuss the company's advancements, including positive results from the ongoing OCU400 Phase 1/2 trial, and outline expected milestones. Investors can also schedule one-on-one meetings with Ocugen's leadership team during the conference.
A live video webcast of the discussion will be available on Ocugen's investor site.
- None.
- None.
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at the Nasdaq Market Site in Times Square, New York City.
Details regarding Ocugen’s fireside chat are as follows:
Event: H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 2, 2023
Time: 11 – 11:30 a.m. EDT
Location: Nasdaq Market Site, New York City, Room 1 West (10th Floor)
Dr. Musunuri will highlight Ocugen’s progress across its integrated pipeline including the Company’s positive preliminary safety and efficacy results from its ongoing OCU400 Phase 1/2 trial and modifier gene therapy platform, as well as provide an overview of anticipated short- and long-term milestones. Ocugen’s leadership team will be available for one-on-one meetings with registered investors throughout the event.
A live video webcast of the fireside chat will be available on the events page of the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
What is the date of the H.C. Wainwright BioConnect Investor Conference where Ocugen will present?
Who will represent Ocugen at the investor conference?
What time is Ocugen's fireside chat at the conference?
Where will the H.C. Wainwright BioConnect Investor Conference be held?
What key topics will Dr. Musunuri discuss during the fireside chat?
Will there be a live stream of Ocugen's presentation at the conference?
